Summary by Allyson Berent, DVM, DACVIM Individuals affected with Angelman syndrome (AS) are known to have limited functional speech and are typically able to
FAST US and FAST AU Announce Joint Funding To Dr. Arthur Beaudet To Generate Mouse Lines Expressing Human UBE3A Antisense
“Of all the childhood genetic neurologic disorders of the brain, Angelman syndrome may be the single best candidate for developing a definitive treatment (
Edwin Weeber, Ph.D. is a Professor in the Department of Molecular Pharmacology and Physiology and the Chief Scientific Officer at the University of South Flo
The FIRE team of FAST turns on Ube3a in mice with Angelman Syndrome….the future gets even MORE promising with Zinc Finger technology.
Read about the recently published paper «Protein Delivery of an Artificial Transcription Factor Restores Widespread Ube3a Expression in an Angelman Syndrome
In March of 2013, the Tampa 24, wrapped up their final visits to Tampa General Hospital for the human clinical trial to test the efficacy of minocycline in t
The Foundation for Angelman Syndrome Therapeutics (“FAST”) is pleased to announce that the 2nd Annual Global Summit on Angelman Syndrome will take place